Pages that link to "Item:Q1699638"
From MaRDI portal
The following pages link to Bayesian two-stage design for phase II clinical trials with switching hypothesis tests (Q1699638):
Displaying 10 items.
- Bayesian predictive monitoring with bivariate binary outcomes in phase II clinical trials (Q1727847) (← links)
- Efficacy and toxicity monitoring via Bayesian predictive probabilities in phase II clinical trials (Q2059113) (← links)
- Seamlessly Expanding a Randomized Phase II Trial to Phase III (Q3079028) (← links)
- Bayesian Optimal Design for Phase II Screening Trials (Q3530110) (← links)
- Phase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian Design (Q4796210) (← links)
- Bayesian two-stage design for drug screening trials with switching hypothesis tests based on continuous endpoints (Q5079049) (← links)
- Stopping for efficacy in single-arm phase II clinical trials (Q5093024) (← links)
- A Bayesian seamless phase I–II trial design with two stages for cancer clinical trials with drug combinations (Q5135528) (← links)
- Bayesian designs with frequentist and Bayesian error rate considerations (Q5424966) (← links)
- Bayesian enhancement two-stage design with error control for phase II clinical trials (Q6617391) (← links)
